22q11.2 deletion syndrome historical perspective

Revision as of 14:36, 3 July 2020 by Ayushijain (talk | contribs)
Jump to navigation Jump to search

22q11.2 deletion syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating 22q11.2 deletion syndrome from other Diseases

Causes

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

22q11.2 deletion syndrome historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 22q11.2 deletion syndrome historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 22q11.2 deletion syndrome historical perspective

CDC on 22q11.2 deletion syndrome historical perspective

22q11.2 deletion syndrome historical perspective in the news

Blogs on 22q11.2 deletion syndrome historical perspective

Directions to Hospitals Treating 22q11.2 deletion syndrome

Risk calculators and risk factors for 22q11.2 deletion syndrome historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayushi Jain, M.B.B.S.

Overview

Historical Perspective

Discovery

DGS characteristics were first described in 1828 but adequately reported later in 1965 by Dr. Angelo DiGeorge, as a clinical trial that included immunodeficiency, hypoparathyroidism, and congenital heart disease.[1]

  • The association between thymic aplasia and DiGeorge syndrome was first noted by Harrington [2] in 1829 and later in association with congenital hypoparathyroidism by Lobdell[3] in 1959.
  • Although by 1979, DiGeorge had evaluated 29 patients, the next important publication on DGS was that of Conley et al[4] on the delineation of the spectrum of DGS. The association of DGS with CHARGE association and of DGS and holoprosencephaly/arhinencephaly were both noted in Conley's series.
  • In 1979, Conley et al[4] pointed out the association of DGS with conotruncal cardiac defects.
  • From the standpoint of pathogenesis and aetiology, Lammer and Opitz[5] wrote a review of the various mechanisms in 1986. Aetiologically, DGA can occur because of various chromosome abnormalities (discussed later), mendelian disorders (including velocardiofacial syndrome (VCFS) and Zellweger syndrome), teratogenic exposure (alcohol, maternal diabetes, retinoids), and other associations (CHARGE associations and with Kallmann syndrome or with holoprosencephaly) (the latter two may be a spectrum of the same defect).

Landmark Events in the Development of Treatment Strategies

Impact on Cultural History

Famous Cases

The following are a few famous cases of [disease name]:

References

  1. McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JA, Zackai EH, Emanuel BS, Vermeesch JR, Morrow BE, Scambler PJ, Bassett AS. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015 Nov 19;1:15071.
  2. Harrington LH. Absence of the thymus gland. Lond Med Gaz 1929;3:314.
  3. Lobdell DH. Congenital absence of the parathyroid glands. Arch Pathol 1959;67:412-18.
  4. 4.0 4.1 Conley ME, Beckwith JB, Mancer JFK, Tenckhoff L. The spectrum of the DiGeorge syndrome. J7 Pediatr 1979;94:883-90.
  5. Lammer EJ, Opitz JM. The DiGeorge anomaly as a developmental field defect. Am J7 Med Genet Suppl 1986;2:1 13-27.

Template:WH Template:WS